NASDAQ · Analyst Forecast

UroGen Pharma Ltd. (URGN) Stock Forecast & Price Target

$29.87 NASDAQ: URGN Market Cap $1.47B

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 18, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering UroGen Pharma Ltd. (URGN), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For UroGen Pharma Ltd., analysts forecast revenue rising from $111.88M in 2025 to $997.89M in 2030; the average estimate for 2030 earnings per share is $7.76; with published estimates ranging from $6.57 to $9.57; 6 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$29.87
Consensus targetThe average of the price targets analysts have published.$58.60
Median targetThe middle target, less affected by a single outlier.$58.00
Highest targetThe most optimistic published target.$75.00
Lowest targetThe most pessimistic published target.$44.00
Difference from priceHow far the consensus target sits from today’s price.+96.2%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$109.04M$111.88M$116.83M6
2026$308.47M$319.50M$327.33M5
2027$472.10M$534.85M$634.77M6
2028$628.80M$761.08M$1.04B6
2029$729.50M$827.01M$975.42M4
2030$880.23M$997.89M$1.18B3

Earnings per share forecast

YearLowAverageHighAnalysts
2025−$3.38−$3.20−$2.986
2026−$0.79−$0.37−$0.115
2027$0.56$2.50$4.406
2028$3.16$5.80$11.066
2029$5.18$6.12$7.544
2030$6.57$7.76$9.573

UroGen Pharma Ltd. (URGN) forecast — frequently asked questions

What is the analyst price target for UroGen Pharma Ltd.?

Analysts covering UroGen Pharma Ltd. (URGN) have a consensus price target of $58.60, 96.2% above the current price of $29.87. Published targets range from $44.00 to $75.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for UroGen Pharma Ltd.'s earnings?

The average analyst estimate for UroGen Pharma Ltd. (URGN) earnings per share in 2030 is 7.76, with individual estimates between 6.57 and 9.57.

How much revenue is UroGen Pharma Ltd. expected to make?

Analysts forecast UroGen Pharma Ltd. (URGN) revenue of $997.89M in 2030, based on 3 published estimates.

How many analysts cover URGN?

6 analysts contribute estimates for UroGen Pharma Ltd. (URGN). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.